Gene Expression Profile and Acute Gene Expression Response to Sclerostin Inhibition in Osteogenesis Imperfecta Bone

Sclerostin antibody (SclAb) therapy has been suggested as a novel therapeutic approach toward addressing the fragility phenotypic of osteogenesis imperfecta (OI). Observations of cellular and transcriptional responses to SclAb in OI have been limited to mouse models of the disorder, leaving a paucit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JBMR Plus
Asıl Yazarlar: Surowiec, Rachel K, Battle, Lauren F, Schlecht, Stephen H, Wojtys, Edward M, Caird, Michelle S, Kozloff, Kenneth M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7422710/
https://ncbi.nlm.nih.gov/pubmed/32803109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10377
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller